NMTC Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Product Revenue: $2.9 million in Q1 2026, down from $3.3 million in Q1 2025 (which included initial stocking from Zimmer). However, this represents a 5.5% increase from $2.7 million in Q4 2025.

License Revenue: None reported in Q1 2026, compared to $3 million in Q1 2025.

Gross Profit: $1.6 million (54.2% of revenue) in Q1 2026, down from $1.9 million (58.9% of revenue) in Q1 2025.

Operating Expenses: Totaled $3.3 million, slightly up from $3.2 million in the prior year. R&D expenses increased to $1.4 million from $1.2 million.

Net Loss: $1.4 million, or $0.03 per share, compared to a net income of $1.8 million, or $0.06 per share, in Q1 2025.

Cash Position: $3.6 million as of December 31, 2025, down from $6.6 million at the end of Q4 2025.

2Strategic Updates and Business Highlights

OneRF Brain Ablation System: Continued adoption with nearly half of all ablations performed since launch occurring in Q1 2026. A patient success story was highlighted, showcasing the system's effectiveness.

Trigeminal Nerve Ablation System: Limited commercial launch initiated with positive outcomes reported from 9 patients treated across 3 centers.

Drug Delivery Program: Accelerated timeline with devices expected for clinical studies by Q3 2026, six months ahead of schedule. Advisory board being formed with oncology experts.

Lower Back Pain Management: Progress on two technologies, with plans for animal studies to begin soon.

Board Appointment: Jason Mills appointed to the Board, bringing valuable experience from Penumbra Inc.

3Forward Guidance and Outlook

Revenue Projection: Anticipating at least $10.5 million in sales for fiscal 2026, representing a minimum 17% increase from fiscal 2025.

Continued Development: Ongoing discussions for strategic partnerships and commercialization efforts, particularly for the trigeminal nerve system.

4Bad News, Challenges, or Points of Concern

Declining License Revenue: The absence of license revenue in Q1 2026 compared to the previous year raises concerns about dependency on product sales.

Net Loss: The company reported a significant net loss compared to the prior year, indicating potential financial strain.

Cash Decrease: The reduction in cash reserves could limit operational flexibility unless revenue milestones are achieved.

5Notable Q&A Insights

Trigeminal System Adoption: 9 cases treated at 3 centers, with all patients reporting pain relief. Discussions with strategic partners are ongoing.

Operational Costs: SG&A expenses expected to remain flat, while R&D costs may fluctuate based on project phases.

Sales and Marketing Responsibility: Zimmer is responsible for all marketing and sales costs, which alleviates some financial burden from NeuroOne.

Revenue Composition: Most Q1 revenue was attributed to restocking rather than new sales, indicating reliance on existing inventory replenishment. Overall, NeuroOne Medical Technologies Corporation is experiencing some growth and positive developments in its product offerings, but faces challenges with revenue consistency and financial losses. The outlook for fiscal 2026 remains cautiously optimistic with strategic initiatives underway.